Is Nonconsensual Tapering of High-Dose Opioid Therapy Justifiable
Bibliographic Data
| ID | 15748115 |
|---|---|
| Authors | Travis N Rieder (0000-0002-2919-8634, Johns Hopkins Berman Institute of Bioethics, corresponding author) |
| Year | 2020 |
| Volume | 22 |
| Issue | 8 |
| Pages | E651-657 |
| Publication date | 2020-09-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | The AMA Journal of Ethic (JOURNAL) |
| Journal identifiers | ISSN: 2376-6980 • E-ISSN: 2376-6980 |
| Publisher | American Medical Association (PUBLISHER • US) |
| DOI | 10.1001/amajethics.2020.651 |
| PMID | 32880351 |
| OpenAlex | W3049184494 |
| Language | EN |
| Citations received | 3 |
| References cited | 3 |
This case considers a so-called legacy patient, one whose behaviors and symptoms express a legacy of past, aggressive opioid prescribing by a clinician. Some prescribers might feel pressured to taper doses of opioids for such patients, but this article argues that nonconsensual dose reductions for stable opioid therapy patients is impermissible because it both puts a patient at risk and wrongs an individual in a misdirected attempt to ameliorate a systemic wrong. Although perhaps surprising, this argument is supported by current evidence and recommendations for patient-centered pain care
Opioid · Tapering · Computer Science · Medicine · Opioid Use Disorder Treatment · Pain Management and Opioid Use · Pain Management and Placebo Effect · Internal Medicine
| Unique citing works | 3 |
|---|---|
| Citations per year | 0,5 |
| Citation span | 2020 - 2022 (3) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 3 |